Akari Therapeutics (AKTX) Non-Current Receivables (2015 - 2022)
Akari Therapeutics recorded quarterly Non-Current Receivables of $6717.0 in Q4 2022, down 23.9% quarter-over-quarter from $8826.0 in Q4 2021, and down 23.9% year-over-year from $8826.0 in Q4 2021.
Akari Therapeutics' Non-Current Receivables history runs 8 years deep, the most recent figure standing at $6717.0 for Q4 2022.
- In Q4 2022, Non-Current Receivables fell 23.9% year-over-year to $6717.0; the TTM figure through Dec 2022 stood at $6717.0 (down 23.9% YoY), while the FY2022 annual figure was $6717.0, down 23.9% from the prior year.
- Non-Current Receivables came in at $6717.0 for Q4 2022 at Akari Therapeutics, down from $8826.0 in the prior quarter.
- In the past five years, Non-Current Receivables ranged from a high of $14452.0 in Q4 2018 to a low of $6717.0 in Q4 2022.
- A 5-year average of $9109.6 and a median of $8152.0 in 2019 frame the typical range for Non-Current Receivables.
- Across the five-year window, Non-Current Receivables sank 43.59% in 2019 and rose 19.25% in 2021, its largest moves.
- Akari Therapeutics' Non-Current Receivables stood at $14452.0 in 2018, then plunged by 43.59% to $8152.0 in 2019, then decreased by 9.21% to $7401.0 in 2020, then increased by 19.25% to $8826.0 in 2021, then declined by 23.9% to $6717.0 in 2022.
- According to Business Quant data, Non-Current Receivables over the past three periods registered $6717.0, $8826.0, and $7401.0 for Q4 2022, Q4 2021, and Q4 2020 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.49 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 6,717.00 |
| Dec 31, 2021 | 8,826.00 |
| Dec 31, 2020 | 7,401.00 |
| Dec 31, 2019 | 8,152.00 |
| Dec 31, 2018 | 14,452.00 |
| Dec 31, 2017 | 13,379.00 |
| Dec 31, 2016 | 5,589.00 |
| Dec 31, 2015 | 4,337.00 |